Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Associated Therapies
-
Clinical Trials
Related News

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: BIIB022
Drug: Sorafenib
First Posted Date
2009-08-11
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
40
Registration Number
NCT00956436
Locations
🇬🇧

Resesarch Site, Edgbaston, Birmingham, United Kingdom

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

First Posted Date
2009-08-10
Last Posted Date
2018-01-03
Lead Sponsor
University of Miami
Target Recruit Count
9
Registration Number
NCT00955721
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Drug: sorafenib
First Posted Date
2009-08-07
Last Posted Date
2019-11-15
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
24
Registration Number
NCT00954278
Locations
🇺🇸

University of Wisconsin - Madison, Madison, Wisconsin, United States

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: 4SC-201
Drug: Sorafenib
First Posted Date
2009-07-22
Last Posted Date
2014-01-16
Lead Sponsor
4SC AG
Target Recruit Count
57
Registration Number
NCT00943449
Locations
🇮🇹

l'Azienda Ospedaliero-Universitaria di Bologna-Policlinico S. Orsola Malpighi, Bologna, Italy

🇩🇪

Universitätsklinikum Hamburg-Eppendorf (I. Medizinische Klinik und Poliklinik), Hamburg, Germany

🇮🇹

Istituto Europea di Oncologia EIO, Milano, Italy

and more 12 locations

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

First Posted Date
2009-07-22
Last Posted Date
2017-03-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
33
Registration Number
NCT00943943
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

First Posted Date
2009-07-21
Last Posted Date
2014-04-29
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
21
Registration Number
NCT00942682
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Phase 3
Completed
Conditions
Kidney Neoplasms
Interventions
Drug: Axitinib (AG-013736)
Drug: Sorafenib
First Posted Date
2009-06-15
Last Posted Date
2022-05-06
Lead Sponsor
Pfizer
Target Recruit Count
492
Registration Number
NCT00920816
Locations
🇺🇸

US Oncology West Region, Henderson, Nevada, United States

🇺🇸

Nebraska Methodist Hospital, Omaha, Nebraska, United States

🇺🇸

Hematology-Oncology Associates of Northern NJ, PA, Parsippany, New Jersey, United States

and more 93 locations

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

First Posted Date
2009-06-12
Last Posted Date
2016-02-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
39
Registration Number
NCT00919061
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

First Posted Date
2009-05-25
Last Posted Date
2018-01-12
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
44
Registration Number
NCT00908167
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

First Posted Date
2009-05-21
Last Posted Date
2018-06-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
47
Registration Number
NCT00906373
Locations
🇺🇸

ImClone Investigational Site, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy